<DOC>
	<DOCNO>NCT03089879</DOCNO>
	<brief_summary>GVGH Shigella Sonnei 1970GAHB vaccine aim prevent disease cause Shigella sonnei . A post-hoc analysis subject participate parent study show significantly different response subject detectable versus undetectable antibody titre baseline , suggest possibility vaccine might sufficiently immunogenic completely naïve adult . This study design characterize immunogenicity profile vaccine evaluate whether able induce immunological memory response .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity 1 Booster Dose 1790GAHB Vaccine Healthy Adults Primed With 3 Doses 1790GAHB Vaccine Study H03_01TP Compared 1 Vaccination 1790GAHB Either Subjects Who Received Placebo Same Study naïve Subjects Not Part H03_01TP Study</brief_title>
	<detailed_description />
	<mesh_term>Dysentery</mesh_term>
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female , age 22 50 year , previously vaccinate , either vaccine ( 3 dos ) placebo , H03_01TP undetectable antibody titer baseline , Males females , age 22 50 year , part H03_01TP . Individuals , nature study explain , prior protocol specific procedure perform , give write consent accord local regulatory requirement . Individuals good health determine outcome medical history , physical examination , hematological blood test clinical judgment investigator . If woman childbearing potential , negative urinary pregnancy test prior study vaccination willingness use acceptable birth control measure entire study duration . Individuals affiliate social security regimen . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study . Individuals progressive severe neurological disorder , seizure disorder GuillainBarré syndrome . Individuals able understand follow require study procedure whole period study . Individuals know hepatitis B C suspect HIV infection HIV related disease history autoimmune disorder know suspected impairment /alteration immune system . Progressive , unstable uncontrolled clinical condition . Hypersensitivity , include allergy , component vaccine , medicinal product medical equipment whose use foreseen study . Individuals know bleed diathesis , condition may associate prolonged bleeding time . Clinical condition represent contraindication intramuscular vaccination blood draw . Abnormal function immune system result : Clinical condition ; Systemic administration corticosteroid 14 consecutive day within 90 day prior informed consent ; Administration antineoplastic immunomodulating agent radiotherapy within 90 day prior informed consent . Received immunoglobulin blood product within 180 day prior informed consent . Study personnel immediate family household member . Any clinical condition , opinion investigator , might interfere result study pose additional risk subject due participation study . Individuals receive investigational product another clinical trial 28 day prior first study visit intent receive another investigational product time conduct study . Individuals receive vaccine within 4 week prior enrollment study planning receive vaccine within entire study duration . Inactivated influenza vaccine give , 4 week earlier 4 week later date immunization . Individuals receive blood , blood product , and/or plasma derivative include parenteral immunoglobulin preparation past 180 day . Individuals body temperature &gt; 38.0 degree Celsius within 3 day intend study vaccination . Individuals Body Mass Index &gt; 30 kg/m2 . Individuals history substance alcohol abuse within past 2 year . Women pregnant breastfeeding , childbearing age use plan use acceptable birth control measure , duration study . Females history stillbirth , neonatal loss , previous infant anomaly . Individuals previously laboratory confirm suspected disease cause S. sonnei . Individuals household contact with/and intimate exposure individual laboratory confirm S. sonnei . Any condition , , opinion investigator may pose increase unreasonable safety risk subject participate present study . Individuals neutrophil count value low 1.8 10^9/L screening assessment . Individuals human leukocyte antigen ( HLA ) B27 positive and/or history reactive arthritis . Previous history Benign Ethnic Neutropenia drug relate Neutropenia and/or concomitant treatment neutropenic agent .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immunogenicity , Vaccine</keyword>
	<keyword>Immunologic Memory</keyword>
	<keyword>GMMA</keyword>
	<keyword>Shigella Vaccines</keyword>
	<keyword>Shigellosis</keyword>
	<keyword>Dysentery , Bacillary</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Safety</keyword>
	<keyword>Bacteria</keyword>
	<keyword>Clinical Trials , Phase 1</keyword>
	<keyword>Shigella sonnei</keyword>
</DOC>